Structural approaches to obtain kinase selectivity

Trends in Pharmacological Sciences

Volumn 33, Issue 5, 2012, Pages 273-278

  Norman, Richard A ^a   Toader, Dorin ^a   Ferguson, Andrew D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ADENOSINE TRIPHOSPHATE; ARQ 069; ARQ 523; AURORA A KINASE; CX 4945; CX 5011; CX 5279; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 8; DORAMAPIMOD; GLYCOGEN SYNTHASE KINASE 3BETA; IMATINIB; JWS 648; MYOSIN LIGHT CHAIN KINASE; P21 ACTIVATED KINASE 1; PD 318088; PD 334581; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOTRANSFERASE; PICTRELISIB; PONATINIB; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; S6 KINASE; SELUMETINIB; SORAFENIB; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 3;

BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME STRUCTURE; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; BINDING SITES; DRUG DESIGN; HUMANS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84860524795     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.03.005     Document Type: Review

References (47)

1. G. Manning The protein kinase complement of the human genome Science 298 2002 1912 1934 (Pubitemid 35425239)
2. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2 2006 358 364 (Pubitemid 43936934)
3. C.D. Mol Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors Curr. Opin. Drug Discov. Dev. 7 2004 639 648 (Pubitemid 39329866)
4. A.D. Ferguson Structural basis of CX-4945 binding to human protein kinase CK2 FEBS Lett. 585 2011 104 110
5. R. Battistutta Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer Biochemistry 50 2011 8478 8488
6. D.J. Huggins Rational approaches to improving selectivity in drug design J. Med. Chem. 55 2012 1424 1444
7. D.D. Robinson Understanding kinase selectivity through energetic analysis of binding site waters Chem. Med. Chem. 5 2010 618 627
8. O. Vadas Structural basis for activation and inhibition of class I phosphoinositide 3-kinases Sci. Signaling 4 2011 1 12
9. A. Berndt The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors Nat. Chem. Biol. 6 2010 117 124
10. T. Heffron Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform J. Med. Chem. 54 2011 7815 7833
11. D. Huang Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis Bioinformatics 26 2010 198 204
12. E. Martin Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity J. Chem. Inf. Model. 51 2011 1942 1956
13. S.S. Taylor, and A.P. Kornev Protein kinases: evolution of dynamic regulatory proteins Trends Biochem. Sci. 36 2011 65 77
14. N. Munshi ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity Mol. Cancer Ther. 9 2010 1544 1553
15. S. Eathiraj Discovery of a novel mode of protein kinase inhibition characterised by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197 J. Biol. Chem. 286 2011 20666 20676
16. S. Eathiraj A novel mode of protein kinase inhibition exploiting hydrophobic motifs of auto-inhibited kinases: discovery of ATP independent inhibitors of fibroblast growth factor receptor (FGFR) J. Biol. Chem. 286 2011 20677 20687
17. T. Schindler Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 289 2000 1938 1942
18. N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat Chem. Biol. 2 2006 358 364 (Pubitemid 43936934)
19. J. Dietrich The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796 Bioorg. Med. Chem. 18 2010 5738 5748
20. H.V. Namboodiri Analysis of imatinib and sorafenib binding to p38α compared with c-Abl and b-Raf provides structural insights for the understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases Biochemistry 49 2010 3611 3618
21. I. Kufareva, and R. Abagyan Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states J. Med. Chem. 51 2008 7921 7932
22. M. Xu Predicting inactive conformations of protein kinases using active structures: conformational selection of Type-II inhibitors PLoS ONE 6 2011 e22644
23. S. Betzi Discovery of a potential allosteric ligand binding site in CDK2 ACS Chem. Biol. 6 2011 492 501
24. E.V. Schneider The structure of CDK8/CycC implicates specificity in the CDK/Cyclin family and reveals interaction with a deep pocket binder J. Mol. Biol. 412 2011 251 266
25. J.F. Ohren Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat. Struct. Mol. Biol. 11 2004 1192 1197
26. T. Yeh Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin. Cancer Res. 13 2007 1576 1583 (Pubitemid 46450450)
27. H. Tecle Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK? Bioorg. Med. Chem. Lett. 19 2009 226 269
28. J.A. Bikker Kinase domain mutations in cancer: implications for small molecule drug design strategies J. Med. Chem. 52 2009 1493 1509
29. D.J. Maly Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors ACS Chem. Biol. 5 2010 121 138
30. C.A. Dodson Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design Biochem. J. 427 2010 19 28
31. X.Y. Lu Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation Curr. Med. Chem. 18 2011 2146 2157
32. T. O'Hare AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16 2009 401 412
33. T. Zhou Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance Chem. Biol. Drug Des. 77 2011 1 11
34. J. Singh Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the ErbB receptor subfamily of protein tyrosine kinases J. Med. Chem. 40 1997 1130 1135 (Pubitemid 27149266)
35. J. Singh The resurgence of covalent drugs Nat. Rev. Drug Discov. 10 2011 307 317
36. M.S. Cohen Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science 308 2005 1318 1321 (Pubitemid 40746129)
37. C.W. Murray, and T.L. Blundell Structural biology in fragment-based drug design Curr. Opin. Struct. Biol. 20 2010 497 507
38. Y. Chen, and B.K. Shoichet Molecular docking and ligand specificity in fragment-based inhibitor discovery Nat. Chem. Biol. 5 2009 358 364
39. S. Barelier Ligand specificity in fragment-based drug design J. Med. Chem. 53 2010 5256 5266
40. P. Bamborough Selectivity of kinase inhibitor fragments J. Med. Chem. 54 2011 5131 5143
41. D.A. Erlanson Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery Bioorg. Med. Chem. Lett. 21 2011 3078 3083
42. L. Feng Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors J. Am. Chem. Soc. 133 2011 5976 5986
43. A. Kastl Dual anticancer activity in a single compound: visible-light-induced apoptosis by an antiangiogenic iridium complex Chem. Commun. 48 2012 1863 1865
44. K.J. Cox Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases Future Med. Chem. 3 2011 29 43
45. P. Cohen The development and therapeutic potential of protein kinase inhibitors Curr. Opin. Chem. Biol. 3 1999 459 465 (Pubitemid 29376108)
46. R. Morphy Selectively nonselective kinase inhibition: striking the right balance J. Med. Chem. 53 2010 1413 1437
47. G.A. Holdgate, and A.L. Gill Kinetic efficiency: the missing metric for enhancing compound quality? Drug Discov. Today 16 2011 910 913